NASDAQ: CHRSCoherus Biosciences Inc Stock
$1.93-0.09 (-4.46%)
Updated Apr 25, 2024
CHRS Price
$1.93
Fair Value Price
$2.87
Market Cap
$217.54M
52 Week Low
$1.43
52 Week High
$8.22
P/E
-0.76x
P/B
-1.12x
P/S
1.22x
PEG
N/A
Dividend Yield
N/A
Revenue
$257.24M
Earnings
-$237.89M
Gross Margin
38.2%
Operating Margin
-76.86%
Profit Margin
-92.5%
Debt to Equity
-4.26
Operating Cash Flow
-$175M
Beta
1.25
Next Earnings
May 6, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CHRS Overview
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. The company also develops Toripalimab, a novel anti-PD-1 antibody for second-line treatment of melanoma in China; Bevacizumab biosimilar; and CHS-1420, an anti-TNF product candidate, as an adalimumab biosimilar; Ranibizumab biosimilar. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; Innovent Biologics (Suzhou) Co., Ltd.; and Junshi Biosciences. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CHRS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CHRS ($1.93) is undervalued by 32.65% relative to our estimate of its Fair Value price of $2.87 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CHRS ($1.93) is significantly undervalued by 32.65% relative to our estimate of its Fair Value price of $2.87 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CHRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CHRS due diligence checks available for Premium users.
Be the first to know about important CHRS news, forecast changes, insider trades & much more!
CHRS News
Valuation
CHRS fair value
Fair Value of CHRS stock based on Discounted Cash Flow (DCF)
Price
$1.93
Fair Value
$2.87
Undervalued by
32.65%
CHRS ($1.93) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CHRS ($1.93) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CHRS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CHRS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.76x
Industry
15.41x
Market
40.97x
CHRS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-1.12x
Industry
5.8x
CHRS's financial health
Profit margin
Revenue
$91.5M
Net Income
-$79.7M
Profit Margin
-87%
CHRS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
CHRS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$629.6M
Liabilities
$823.0M
Debt to equity
-4.26
CHRS's short-term assets ($475.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CHRS's long-term liabilities ($491.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CHRS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CHRS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$12.9M
Investing
$35.2M
Financing
$366.0k
CHRS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CHRS vs Biotech Stocks
Coherus Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.